Unicycive Historical Financial Ratios
| UNCY Stock | USD 0.69 0.01 1.47% |
Unicycive Therapeutics is promptly reporting on over 79 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 0.0 will help investors to properly organize and evaluate Unicycive Therapeutics financial condition quickly.
Unicycive |
About Unicycive Financial Ratios Analysis
Unicycive TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Unicycive Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Unicycive financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Unicycive Therapeutics history.
Unicycive Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Unicycive Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Unicycive Therapeutics sales, a figure that is much harder to manipulate than other Unicycive Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Unicycive Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Current Ratio is likely to rise to 1.39 in 2024, whereas PTB Ratio is likely to drop (5.87) in 2024.
| 2023 | 2024 (projected) | Interest Debt Per Share | 0.004075 | 0.003871 | Revenue Per Share | 0.0275 | 0.0498 |
Unicycive Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Unicycive Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Unicycive Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (47.65) | (28.54) | 1.87 | (17.45) | (5.59) | (5.87) | |
| Free Cash Flow Yield | (0.0279) | (0.0191) | (0.19) | (1.93) | (0.86) | (0.9) | |
| Operating Cash Flow Per Share | (0.14) | (0.0957) | (0.38) | (1.04) | (0.75) | (0.78) | |
| Pb Ratio | (47.65) | (28.54) | 1.87 | (17.45) | (5.59) | (5.87) | |
| Free Cash Flow Per Share | (0.14) | (0.0957) | (0.39) | (1.04) | (0.75) | (0.78) | |
| Roic | 4.93 | 14.25 | (0.57) | 58.06 | 5.48 | 5.21 | |
| Net Income Per Share | (0.27) | (0.16) | (0.71) | (1.2) | (1.24) | (1.31) | |
| Pocfratio | (35.82) | (52.25) | (5.36) | (0.52) | (1.16) | (1.22) | |
| Pfcf Ratio | (35.82) | (52.25) | (5.33) | (0.52) | (1.16) | (1.22) | |
| Income Quality | 0.54 | 0.64 | 0.58 | 0.87 | 0.6 | 0.52 | |
| Roe | 2.61 | 0.94 | (0.64) | 38.76 | 8.02 | 6.75 | |
| Ev To Operating Cash Flow | (36.2) | (53.97) | (2.54) | (0.5) | (0.68) | (0.71) | |
| Pe Ratio | (18.28) | (30.4) | (2.91) | (0.45) | (0.7) | (0.73) | |
| Return On Tangible Assets | (121.26) | (12.29) | (0.57) | (6.41) | (2.15) | (2.26) | |
| Ev To Free Cash Flow | (36.2) | (53.97) | (2.52) | (0.5) | (0.68) | (0.71) | |
| Earnings Yield | (0.0547) | (0.0329) | (0.34) | (2.22) | (1.43) | (1.51) | |
| Current Ratio | 0.021 | 0.071 | 8.75 | 0.81 | 0.76 | 1.39 | |
| Graham Number | 0.8 | 0.81 | 4.19 | 0.91 | 2.08 | 1.26 | |
| Debt To Equity | (0.52) | (0.94) | 0.00916 | (0.33) | (0.004726) | (0.004962) | |
| Interest Debt Per Share | 0.0711 | 0.18 | 0.0519 | 0.0107 | 0.004075 | 0.003871 | |
| Debt To Assets | 24.21 | 12.32 | 0.008056 | 0.055 | 0.001268 | 0.001205 | |
| Short Term Coverage Ratios | (2.56) | (0.58) | (38.19) | (100.97) | (1.0K) | (964.94) | |
| Price Earnings Ratio | (18.28) | (30.4) | (2.91) | (0.45) | (0.7) | (0.73) | |
| Price Book Value Ratio | (47.65) | (28.54) | 1.87 | (17.45) | (5.59) | (5.87) | |
| Price To Operating Cash Flows Ratio | (35.82) | (52.25) | (5.36) | (0.52) | (1.16) | (1.22) | |
| Price To Free Cash Flows Ratio | (35.82) | (52.25) | (5.33) | (0.52) | (1.16) | (1.22) | |
| Effective Tax Rate | (0.0642) | (0.11) | (0.0614) | (3.32E-4) | (3.82E-4) | (3.63E-4) | |
| Company Equity Multiplier | (0.0215) | (0.0764) | 1.14 | (6.05) | (3.73) | (3.54) | |
| Total Debt To Capitalization | (1.08) | (16.01) | 0.009077 | (0.5) | (0.004748) | (0.004985) | |
| Return On Capital Employed | 2.22 | 0.76 | (0.54) | 38.74 | 6.21 | 6.42 | |
| Debt Equity Ratio | (0.52) | (0.94) | 0.00916 | (0.33) | (0.004726) | (0.004962) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.